|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Biological half-life||6–11 h|
|Excretion||Feces (68%), urine (16%)|
|CAS Registry Number|
Naloxegol (INN; NKTR-118), or PEGylated naloxol, trade name Movantik, is a peripherally-selective opioid antagonist developed by AstraZeneca, licensed from Nektar, for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Doses of 25 mg were found safe and well tolerated for 52 weeks. Adverse gastrointestinal reactions increased in methadone patients and were sometimes severe.
Naloxegol was previously a schedule 2 drug because of its chemical similarity to opium alkaloids. It was recently reclassified as a legend drug after the FDA concluded that it was not habit-forming.
- Roland Seifert; Thomas Wieland; Raimund Mannhold; Hugo Kubinyi; Gerd Folkers (17 July 2006). G Protein-Coupled Receptors as Drug Targets: Analysis of Activation and Constitutive Activity. John Wiley & Sons. p. 227. ISBN 978-3-527-60695-5. Retrieved 14 May 2012.
- "Nektar | R&D Pipeline | Products in Development | CNS/Pain | Oral Naloxegol (NKTR-118) and Oral NKTR-119". Retrieved 2012-05-14.
- "FDA approves MOVANTIK™ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain". 16 September 2014.
- "Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.". Aliment Pharmacol Ther. Oct 2014. PMID 25112584.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|